France headquartered CDMO, Delpharm, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Centre from Dr Reddy's in the Netherlands.
Life science investor group, Novo Holdings, has agreed to buy Ritedose, the largest sterile CDMO in the US focused on advanced blow-fill-seal technology, from Hong-Kong based, AGIC Capital, and China’s Humanwell.
3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).
Excipient producer, DFE Pharma, is expanding its reach, capitalizing on increasing growth in the biologics sector, and launching a new sucrose stabilizer.
Increasing prevalence of chronic diseases and treatment with biologics is expected to boost the prefilled syringes market by 10% in the next few years.